EMA Releases HIV Treatment Guideline for Consultation
EMA revises HIV treatment guideline.
The European Medicines Agency (EMA) has released a draft revision of its guideline on the clinical development of medicines for the treatment of HIV infection, for a six-month public consultation. Comments are being accepted until March 31, 2014.
The proposed revision takes into account developments in HIV treatments that have occurred in the past few years, particularly the use of new, potent antiretroviral agents (ARTs). The guideline outlines a new definition of populations included in clinical trials, moving away from a focus on treatment history to an emphasis on documented viral resistance. Guidance is provided on the development programs and type of data that should be provided for new ARTs.
Source: European Medicines Agency
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
